SANDY, Utah–CODX, (BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today upcoming meetings with the Ministry of Public Health and Social Assistance (SESPAS) of the Dominican Republic to discuss the Company’s products.
The meetings will take place the week of October 16, 2017, with senior officials of the Centro Nacional de Control de Enfermedades Tropicales (National Center of Control of Tropical Diseases, or CEDCET), a division of SESPAS responsible for the prevention and control of malaria, dengue, intestinal parasites, Schistosomiasis (Bilharziasis), and the elimination of lymphatic filariasis for the 10.65 million residents of the Dominican Republic. Co-Diagnostics representatives will present the both the Company’s Zika virus and tuberculosis qPCR tests as diagnostic solutions to those diseases in the region, and will demonstrate diagnostic equipment for which the Company is an authorized reseller. The equipment and tests are optimized to work together to provide complete diagnostics systems to laboratories worldwide that are in need of upgraded facilities, and highly accurate molecular tests and analysis at competitive prices.
Co-Diagnostics CEO Dwight Egan commended: “Our ability to provide diagnostics at affordable prices is the cornerstone of our commitment to underserved populations in regions like the Dominican Republic. Our proprietary design and technology platform allows us to do so not only more affordably, but also via state-of-the-art technology that represents a leap forward in the understanding of real-time PCR molecular diagnostics, now recognized as the gold standard in disease detection.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.